An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein—short review
| Autor: | Sahana Pai, K. Sreedhara Ranganath Pai, Jayesh Mudgal, B. Venkatesh Kamath |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Gene Expression Regulation
Viral 0301 basic medicine Anti-HIV Agents medicine.medical_treatment 030106 microbiology Human immunodeficiency virus (HIV) Integrase inhibitor ABX464 HIV Infections Pharmacy Review Rev protein Rev Protein medicine.disease_cause Nucleoside Reverse Transcriptase Inhibitor 03 medical and health sciences Drug Delivery Systems Pharmacotherapy HIV-1 infections medicine Humans Pharmacology Protease business.industry Latent HIV-1 infection virus diseases rev Gene Products Human Immunodeficiency Virus General Medicine Virology Reverse transcriptase 030104 developmental biology HIV-1 business |
| Zdroj: | Pharmacological Reports |
| ISSN: | 2299-5684 1734-1140 |
| DOI: | 10.1007/s43440-021-00257-9 |
| Popis: | Human immunodeficiency virus-1 (HIV-1) infection remains to be one of the major threats throughout the world. Many researchers are working in this area to find a cure for HIV-1. The group of the FDA approved drugs which are currently used against HIV-1 in the clinical practice include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (InIs), and protease inhibitors (PIs). Fixed dose combinations (FDCs) of these drugs are available and are used as per the anti-retroviral therapy (ART) guidelines. Despite these, unfortunately, there is no cure for HIV1 infection to date. The present review is focused upon describing the importance of a post-transcriptional regulatory protein “Rev”, responsible for latent HIV-1 infection as a possible, and promising therapeutic target against HIV-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink